Velázquez-López L, Sil-Acosta MJ, Goycochea-Robles MV, Escobedo-De la Peña J, Castañeda-Limones R

Language: Spanish
References: 30
Page: 11-18
PDF size: 147.15 Kb.

ABSTRACT

Objective: to evaluate a personalized diet customize for present comorbidity, on metabolic control indicators and renal function.
Methods: a non-randomized clinical trial was conducted during a three-month period in a group of patients with microalbuminuria and in a group with macroalbuminuria. The patients received personalized dietary counseling customize to their comorbidity (obesity, hypertension, and dislypidemia). The effect of the diet was measured through metabolic control variables: body mass index (BMI), waist circumference, fasting glucose levels, glycated hemoglobin (HbA₁c) and lipids profile; the renal function variables were: glomerular filtration rate (GFR) and urine albumin excretion (UAE). Statistical analysis was done with T-paired test.
Results: thirty-nine patients were included (21 women and 18 men). After the intervention, the weight and waist circumference had significantly decreased (p = 0.01); the fasting glucose levels and HbA1c were significantly lower (p = 0.001). The HDL-cholesterol increased significantly (p = 0.009); UAE decreased significantly in patients with micro and macroalbuminuria; 123.0 ± 73.4 to 105.3 ± 61.3 mg/24-h; p = 0.040 and 1482.7 ± 1200.6 to 1093.5 ± 601.8 mg/24-h; p = 0.02. The GFR increased in both groups: 68.9 ± 35.4 to 74.7 ± 41.6 mL/min, p = 0.04; and 62.2 ± 26.6 to 68.5 ± 25.3 mL/min, p = 0.02.
Conclusions: the dietary intervention improved the metabolic control and renal function in type 2 diabetes patients with comorbidity.

REFERENCES

1. Striker GE, Agodoa LL, Held P, Doi T, Conti F, Striker LJ. Kidney disease of diabetes mellitus (diabetic nephropathy): perspectives in the United States. J Diabet Complications 1991;5(2-3):51-52.

2. Gross JL, Azevedo MJ, Silveiro SP, Canani LH, Caramori M, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28(1):164-176.

3. Arredondo A, Zúñiga A. Economic consequences of epidemiological changes in diabetes in middleincome countries. Diabetes Care 2004;27(1):104-108.

4. Escobedo-de la Peña J, Rico-Verdín B. Incidencia de las complicaciones de la diabetes mellitus. Salud Publica Mex 1996;38:236-242.

5. Su HL, Abascal MA, Méndez BF, Paniagua R, Amato D. Epidemiologic and demographic aspects of peritoneal dialysis. Perit Dial Int 1996; 16:362-365.

6. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes; the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63(1):225-232.

7. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-853.

8. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720.

9. Remuzzi G, Ruggenenti P, Perna A, Dimitrov BD, de Zeeuw D, Hille DA, Shahinfar S, Carides GW, Brenner BM. RENAAL Study Group. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004;15(12):3117-3125.

10. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996; 24(7):627-632.

11. Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998;31(6):954-961.

12. Pomerleau J, Verdy M, Garrel DR, Nadeu MH. Effect of protein intake on glycemic control and renal function in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993;36(9):829-834.

13. Pijls LT, de Vries H, Donker AJ, van Eijk JT. The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transplant 1999;14(6): 1445-1453.

14. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996;49(6):1774-1777.

15. Pijls LT, de Vries H, Van Eijk JT, Donker AJ. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Eur J Clin Nutr 2002; 56(12):1200-1207.

16. Facchini FS, Saylor KL. A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes 2003;52(5):1204-1209.

17. Riley MD, Dwyer T. Microalbuminuria is positively associated with usual dietary saturated fat acid intake and negatively associated with usual dietary protein intake in people with insulin-dependent diabetes mellitus. Am J Clin Nutr 1998;67(1):50-57.

18. Tapia Conver R. Modificación a la Norma oficial mexicana NOM-015-SSA2-1994, para la prevención, tratamiento y control de la diabetes mellitus en la atención primaria para quedar como Norma oficial mexicana NOM-015-SSA2-1994, para la prevención, tratamiento y control de la diabetes. México: SSa; 2000.

19. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. J Am Diet Assoc 2002;102(1):109-118.

20. Castañeda- Limones R, Sil-Acosta MJ, Velásquez-López L, Galindo-Salinas MT, Torres-Tamayo M. La nefropatía diabética es un problema frecuente en los pacientes con diabetes mellitus tipo 2 en el primer nivel de atención. En: Martínez SH, Villasís KM, Torres LJ, Gómez DA, editores. Las múltiples facetas de la investigación en salud 4. Distrito Federal: México: IMSS; 2005. p. 152-169.

21. Leza-Torres O, Briones-Lara E, González-Madrazo MA, Cruz-Martínez MC, Ramos-Dávila E. Microalbuminuria en pacientes con diabetes tipo 2. Rev Med IMSS 2005;43(6):487-493.

22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;8(6): 499-502.

23. Kesteloot H, Joossens JV. On the determinants of creatinine clearance: a population study. J Hum Hypertens 1996;10(4):245-249.

24. Amato-Martínez JD, Paniagua-Sierra JR, Álvarez-Aguilar C. Prevalencia de insuficiencia renal crónica en la población derechohabiente del Instituto Mexicano del Seguro Social. En: García PM, Reyes MH, Viniegra VL, editores. Las múltiples facetas de la investigación en salud. México: IMSS; 2001. p. 153-170.

25. Fried L, Orchard T, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59(1):260-269.

26. Wheeler M, Fineberg S, Fineberg N, Gibson R, Hackward L. Animal versus plant protein meals in individuals with type 2 diabetes and microalbuminuria. Effects on renal, glycemic, and lipid parameters. Diabetes Care 2002;25(8)1277-1282.

27. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a metaanalysis. Am J Clin Nutr 1992;56(2):320-328.

28. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310(6):356-360.

29. Hansen HP, Christensen PK, Tauber-Lassen E, Klausen A, Jensen BR, Parving HH. Low-protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy. Kidney Int 1999;55(2):621-628.

30. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991;324(2):1743-1744.